摘要
目的探讨解毒酶基因谷胱甘肽硫转移酶M1(GSTM 1)多态性与黄曲霉毒素B1(AFB1) 相关性肝细胞癌(HCC)风险的相关性。方法应用聚合酶链反应技术对广西地区AFB1高污染区140 例HCC患者和536例对照人群的GSTM1基因多态性进行检测,进行以医院为基础的病例对照研究。结果(1)GSTM1-present基因型为HCC保护基因型,而GSTM1-null基因型为HCC风险基因型,其校正风险值OR(95%可信区间CI)为2.07(1.20-3.5 7);(2)在AFB1暴露中低度与高度两个层次, GSTM1基因多态性均增加HCC危险性,其校正OR(95%CI)分别为1.92(0.92-4.00)和1.80(0.77- 4.17)。结论解毒酶基因GSTM1多态性与HCC易患性相关,其缺失型增加患HCC风险;GSTM1在中低度和高度AFB1暴露时均与HCC易患性相关,但在中低度暴露时更明显。
Objective To investigate the association between susceptibility to aflatoxin Bl（AFBl）-related hepatocellular carcinoma （HCC） and the polymorphism of detoxication gene GSTMI. Methods The peripheral white blood cell DNA samples were obtained from all the subjects including 140 HCC cases and 536 controls from an AFBI high risk area in Guangxi province. The GSTMI polymorphism was detected using PCR technique. Results （1） The GSTM1-present was associated with a decreased HCC risk. The GSTM1-null was associated with an increased HCC risk [adjusted OR （95% CI）= 2.07 （1.20-3.57）]. （2） In the cohorts of both low/median and high exposure levels of AFBI, GSTM1- null genotype was associated with a conspicuous significantly increased risk for HCC [adjusted OR （95% CI） = 1.92 （0.92-4.00） and 1.80 （0.77-4.17）]. Conclusion The results suggest that genetic polymorphism of GSTMI was susceptible to HCC and individuals who are GSTMI-null have an increased risk of developing HCC. There is evidence of interaction between GSTMI polymorphism and AFB 1 exposure, especially with low/median degrees of AFB 1 exposure.
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2005年第9期668-670,共3页
Chinese Journal of Hepatology
基金
国家自然科学基金(39860032)广西教育厅重点资助项目(98-2-8)
